FDA approves Nexviazyme for late-onset Pompe disease
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
The government has recently enhanced the incentive granted to storeowners from existing Rs. 2.50 lakh to Rs. 5.00 lakh given at the rate of 15% of monthly purchases made, subject to a ceiling of Rs. 15,000 per month
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Filing for WHO Emergency Use Authorisation this month
This work has been published in the journal ‘ACS applied materials and interface’
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
PAT rises to Rs 195.76 crore
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Subscribe To Our Newsletter & Stay Updated